Literature DB >> 31262744

Mitochondrial Homeostasis in AML and Gasping for Response in Resistance to BCL2 Blockade.

Michael R Savona1,2, Jeffrey C Rathmell2,3.   

Abstract

Understanding resistance to BCL2 inhibition is a critical scientific and clinical challenge. In this issue of Cancer Discovery, two laboratories use unbiased approaches of large loss-of-function CRISPR/Cas 9 screens to discover targetable liabilities in cell signaling and metabolism to acute myeloid leukemia resistant to BCL2 inhibition.See related article by Chen et al., p. 890.See related article by Nechiporuk et al., p. 910. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31262744      PMCID： PMC8059329          DOI： 10.1158/2159-8290.CD-19-0510

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  15 in total

1.  The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

Authors:  Tamilla Nechiporuk; Stephen E Kurtz; Olga Nikolova; Tingting Liu; Courtney L Jones; Angelo D'Alessandro; Rachel Culp-Hill; Amanda d'Almeida; Sunil K Joshi; Mara Rosenberg; Cristina E Tognon; Alexey V Danilov; Brian J Druker; Bill H Chang; Shannon K McWeeney; Jeffrey W Tyner
Journal:  Cancer Discov       Date:  2019-05-02       Impact factor: 39.397

2.  Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.

Authors:  Xufeng Chen; Christina Glytsou; Hua Zhou; Sonali Narang; Denis E Reyna; Andrea Lopez; Theodore Sakellaropoulos; Yixiao Gong; Andreas Kloetgen; Yoon Sing Yap; Eric Wang; Evripidis Gavathiotis; Aristotelis Tsirigos; Raoul Tibes; Iannis Aifantis
Journal:  Cancer Discov       Date:  2019-05-02       Impact factor: 39.397

3.  Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.

Authors:  Courtney L Jones; Brett M Stevens; Angelo D'Alessandro; Julie A Reisz; Rachel Culp-Hill; Travis Nemkov; Shanshan Pei; Nabilah Khan; Biniam Adane; Haobin Ye; Anna Krug; Dominik Reinhold; Clayton Smith; James DeGregori; Daniel A Pollyea; Craig T Jordan
Journal:  Cancer Cell       Date:  2018-11-12       Impact factor: 31.743

4.  Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.

Authors:  Daniel A Pollyea; Brett M Stevens; Courtney L Jones; Amanda Winters; Shanshan Pei; Mohammad Minhajuddin; Angelo D'Alessandro; Rachel Culp-Hill; Kent A Riemondy; Austin E Gillen; Jay R Hesselberth; Diana Abbott; Derek Schatz; Jonathan A Gutman; Enkhtsetseg Purev; Clayton Smith; Craig T Jordan
Journal:  Nat Med       Date:  2018-11-12       Impact factor: 53.440

Review 5.  TRKing down an old oncogene in a new era of targeted therapy.

Authors:  Aria Vaishnavi; Anh T Le; Robert C Doebele
Journal:  Cancer Discov       Date:  2014-12-19       Impact factor: 39.397

6.  BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.

Authors:  Kristopher A Sarosiek; Xiaoke Chi; John A Bachman; Joshua J Sims; Joan Montero; Luv Patel; Annabelle Flanagan; David W Andrews; Peter Sorger; Anthony Letai
Journal:  Mol Cell       Date:  2013-09-26       Impact factor: 17.970

7.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

Authors:  Eleni D Lagadinou; Alexander Sach; Kevin Callahan; Randall M Rossi; Sarah J Neering; Mohammad Minhajuddin; John M Ashton; Shanshan Pei; Valerie Grose; Kristen M O'Dwyer; Jane L Liesveld; Paul S Brookes; Michael W Becker; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2013-01-17       Impact factor: 24.633

8.  A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.

Authors:  Haley E Ramsey; Melissa A Fischer; Taekyu Lee; Agnieszka E Gorska; Maria Pia Arrate; Londa Fuller; Kelli L Boyd; Stephen A Strickland; John Sensintaffar; Leah J Hogdal; Gregory D Ayers; Edward T Olejniczak; Stephen W Fesik; Michael R Savona
Journal:  Cancer Discov       Date:  2018-09-05       Impact factor: 39.397

9.  Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction.

Authors:  Xi Wang; Madhavi Bathina; John Lynch; Brian Koss; Christopher Calabrese; Sharon Frase; John D Schuetz; Jerold E Rehg; Joseph T Opferman
Journal:  Genes Dev       Date:  2013-06-15       Impact factor: 11.361

10.  Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.

Authors:  Andrew H Wei; Stephen A Strickland; Jing-Zhou Hou; Walter Fiedler; Tara L Lin; Roland B Walter; Anoop Enjeti; Ing Soo Tiong; Michael Savona; Sangmin Lee; Brenda Chyla; Relja Popovic; Ahmed Hamed Salem; Suresh Agarwal; Tu Xu; Kaffa M Fakouhi; Rod Humerickhouse; Wan-Jen Hong; John Hayslip; Gail J Roboz
Journal:  J Clin Oncol       Date:  2019-03-20       Impact factor: 44.544
View more
  9 in total

Review 1.  Natural Antioxidants Improve the Vulnerability of Cardiomyocytes and Vascular Endothelial Cells under Stress Conditions: A Focus on Mitochondrial Quality Control.

Authors:  Xing Chang; Zhenyu Zhao; Wenjin Zhang; Dong Liu; Chunxia Ma; Tian Zhang; Qingyan Meng; Peizheng Yan; Longqiong Zou; Ming Zhang
Journal:  Oxid Med Cell Longev       Date:  2021-01-22       Impact factor: 6.543

2.  Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia.

Authors:  Lucille Stuani; Carine Joffre; Claudie Bosc; Estelle Saland; Aurélie Bousard; Noémie Gadaud; Marie Sabatier; Guillaume Cognet; Thomas Farge; Emeline Boet; Mathilde Gotanègre; Nesrine Aroua; Pierre-Luc Mouchel; Nathaniel Polley; Clément Larrue; Eléonore Kaphan; Muriel Picard; Ambrine Sahal; Latifa Jarrou; Marie Tosolini; Florian Rambow; Florence Cabon; Nathalie Nicot; Laura Poillet-Perez; Yujue Wang; Xiaoyang Su; Quentin Fovez; Jérôme Kluza; Rafael José Argüello; Céline Mazzotti; Hervé Avet-Loiseau; François Vergez; Jérôme Tamburini; Jean-Jacques Fournié; Ing S Tiong; Andrew H Wei; Tony Kaoma; Jean-Christophe Marine; Christian Récher; Jean-Emmanuel Sarry
Journal:  Nat Cancer       Date:  2021-11-11

Review 3.  The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs.

Authors:  Sarah T Diepstraten; Mary Ann Anderson; Peter E Czabotar; Guillaume Lessene; Andreas Strasser; Gemma L Kelly
Journal:  Nat Rev Cancer       Date:  2021-10-18       Impact factor: 60.716

4.  Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.

Authors:  Rachel Thijssen; Sarah T Diepstraten; Donia Moujalled; Edward Chew; Christoffer Flensburg; Melissa X Shi; Michael A Dengler; Veronique Litalien; Sarah MacRaild; Maoshan Chen; Natasha S Anstee; Boris Reljić; Sarah S Gabriel; Tirta M Djajawi; Chris D Riffkin; Brandon J Aubrey; Catherine Chang; Lin Tai; Zhen Xu; Thomas Morley; Giovanna Pomilio; Claudia Bruedigam; Axel Kallies; David A Stroud; Ashish Bajel; Ruth M Kluck; Steven W Lane; Marie Schoumacher; Sébastien Banquet; Ian J Majewski; Andreas Strasser; Andrew W Roberts; David C S Huang; Fiona C Brown; Gemma L Kelly; Andrew H Wei
Journal:  Blood       Date:  2021-05-20       Impact factor: 22.113

5.  ZNF143 Suppresses Cell Apoptosis and Promotes Proliferation in Gastric Cancer via ROS/p53 Axis.

Authors:  Yi Zhang; Qing Li; Song Wei; Jing Sun; Xuan Zhang; Ling He; Lu Zhang; Zekuan Xu; Dexuan Chen
Journal:  Dis Markers       Date:  2020-01-28       Impact factor: 3.434

6.  Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis.

Authors:  Jingyi Zhang; Yuetong Wang; Chujie Yin; Ping Gong; Zhenwei Zhang; Linxiang Zhao; Samuel Waxman; Yongkui Jing
Journal:  Cell Death Dis       Date:  2022-04-20       Impact factor: 8.469

Review 7.  Insights Into the Role of Mitochondria in Vascular Calcification.

Authors:  Z L Zeng; Qing Yuan; Xuyu Zu; Jianghua Liu
Journal:  Front Cardiovasc Med       Date:  2022-04-29

8.  Clinically Relevant Oxygraphic Assay to Assess Mitochondrial Energy Metabolism in Acute Myeloid Leukemia Patients.

Authors:  Quentin Fovez; William Laine; Laure Goursaud; Celine Berthon; Nicolas Germain; Claire Degand; Jean-Emmanuel Sarry; Bruno Quesnel; Philippe Marchetti; Jerome Kluza
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.639

9.  Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia.

Authors:  Dan Cojocari; Brianna N Smith; Julie J Purkal; Maria P Arrate; Jason D Huska; Yu Xiao; Agnieszka Gorska; Leah J Hogdal; Haley E Ramsey; Erwin R Boghaert; Darren C Phillips; Michael R Savona
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.